Search

Your search keyword '"Parekh, Samir"' showing total 1,062 results
Start Over Author "Parekh, Samir"
1,062 results on '"Parekh, Samir"'

201. Immunomodulation in Pomalidomide, Dexamethasone, and Daratumumab-Treated Patients with Relapsed/Refractory Multiple Myeloma

Author

Pierceall, William E., primary, Amatangelo, Michael D., additional, Bahlis, Nizar J., additional, Siegel, David S., additional, Rahman, Adeeb, additional, Van Oekelen, Oliver, additional, Neri, Paola, additional, Young, Mary, additional, Chung, Weiyuan, additional, Serbina, Natalya, additional, Parekh, Samir, additional, Agarwal, Amit, additional, and Thakurta, Anjan, additional

Published
2020
Full Text
View/download PDF

204. Effect of Intravenous Immunoglobulin on Infections in Multiple Myeloma (MM) Patients Receiving Daratumumab

Author

Lancman, Guido, primary, Sastow, Dahniel, additional, Aslanova, Minira, additional, Moshier, Erin, additional, Cho, Hearn Jay, additional, Jagannath, Sundar, additional, Madduri, Deepu, additional, Parekh, Samir, additional, Richard, Shambavi, additional, Richter, Joshua, additional, Sanchez, Larysa, additional, and Chari, Ajai, additional

Published
2020
Full Text
View/download PDF

205. 289 PGV-001: a phase 1 trial of a personalized neoantigen peptide vaccine for the treatment of malignancies in the adjuvant setting

Author

Marron, Thomas, primary, Kodysh, Julia, additional, Rubinsteyn, Alex, additional, Finnigan, John, additional, Blazquez, Ana, additional, Saxena, Mansi, additional, Meseck, Marcia, additional, O’Donnell, Timothy, additional, Delbeau, Daniela, additional, Galsky, Matthew, additional, Doroshow, Deborah, additional, Miles, Brett, additional, Misiukiewicz, Krysztof, additional, Irie, Hanna, additional, Tiersten, Amy, additional, Parekh, Samir, additional, Posner, Marshall, additional, Wolf, Andrea, additional, Mandeli, John, additional, Hammerbacher, Jeffrey, additional, Donovan, Michael, additional, Brody, Rachel, additional, Gnjatic, Sacha, additional, Schadt, Eric, additional, Friedlander, Philip, additional, and Bhardwaj, Nina, additional

Published
2020
Full Text
View/download PDF

206. 90 Potentiation of T-cell mediated tumor killing via modulation of the fas/fasL pathway

Author

Boiarsky, Jonathan, primary, Upadhyay, Ranjan, additional, Svensson-Arvelund, Judit, additional, Wroblewska, Aleksandra, additional, Bhalla, Sherry, additional, Scholler, Nathalie, additional, Bot, Adrian, additional, Rossi, John, additional, Parekh, Samir, additional, Sadek, Norah, additional, Baccarini, Alessia, additional, Merad, Miriam, additional, Brown, Brian, additional, and Brody, Joshua, additional

Published
2020
Full Text
View/download PDF

207. Patient Similarity Network of Newly Diagnosed Multiple Myeloma Identifies Patient Sub-groups with Distinct Genetic Features and Clinical Implications

Author

Bhalla, Sherry, primary, Melnekoff, David, additional, Keats, Jonathan, additional, Onel, Kenan, additional, Sawyer, Jeffrey, additional, Madduri, Deepu, additional, Richter, Joshua, additional, Richard, Shambavi, additional, Chari, Ajai, additional, Cho, Hearn, additional, Dudley, Joel, additional, Jagannath, Sundar, additional, Lagana, Alessandro, additional, and Parekh, Samir, additional

Published
2020
Full Text
View/download PDF

211. Myeloma CAR-T CRS Management With IL-1R Antagonist Anakinra

Author

Jatiani, Shashidhar S., primary, Aleman, Adolfo, additional, Madduri, Deepu, additional, Chari, Ajai, additional, Cho, Hearn Jay, additional, Richard, Shambavi, additional, Richter, Joshua, additional, Brody, Joshua, additional, Jagannath, Sundar, additional, and Parekh, Samir, additional

Published
2020
Full Text
View/download PDF

213. A phase II study of pomalidomide, daily oral cyclophosphamide, and dexamethasone in relapsed/refractory multiple myeloma

Author

Van Oekelen, Oliver, primary, Parekh, Samir, additional, Cho, Hearn J., additional, Vishnuvardhan, Nivetha, additional, Madduri, Deepu, additional, Richter, Joshua, additional, Ip, Chun, additional, Lau, Kenneth, additional, Florendo, Erika, additional, Mancia, Ines S., additional, Thomas, Joanne, additional, Verina, Daniel, additional, Chan, Elaine, additional, Zarychta, Katarzyna, additional, La, Lisa, additional, Strumolo, Gina, additional, Melnekoff, David T., additional, Leshchenko, Violetta V., additional, Kim-Schulze, Seunghee, additional, Couto, Suzana, additional, Wang, Maria, additional, Pierceall, William E., additional, Thakurta, Anjan, additional, Laganà, Alessandro, additional, Jagannath, Sundar, additional, and Chari, Ajai, additional

Published
2020
Full Text
View/download PDF

214. A tertiary center experience of multiple myeloma patients with COVID-19: lessons learned and the path forward

Author

Wang, Bo, primary, Van Oekelen, Oliver, additional, Mouhieddine, Tarek H., additional, Del Valle, Diane Marie, additional, Richter, Joshua, additional, Cho, Hearn Jay, additional, Richard, Shambavi, additional, Chari, Ajai, additional, Gnjatic, Sacha, additional, Merad, Miriam, additional, Jagannath, Sundar, additional, Parekh, Samir, additional, and Madduri, Deepu, additional

Published
2020
Full Text
View/download PDF

215. An inflammatory cytokine signature helps predict COVID-19 severity and death

Author

Del Valle, Diane Marie, primary, Kim-schulze, Seunghee, additional, Hsin-hui, Huang, additional, Beckmann, Noam D, additional, Nirenberg, Sharon, additional, Wang, Bo, additional, Lavin, Yonit, additional, Swartz, Talia, additional, Madduri, Deepu, additional, Stock, Aryeh, additional, Marron, Thomas, additional, Xie, Hui, additional, Patel, Manish Kumar, additional, van Oekelen, Oliver, additional, Rahman, Adeeb, additional, Kovatch, Patricia, additional, Aberg, Judith, additional, Schadt, Eric, additional, Jagannath, Sundar, additional, Mazumdar, Madhu, additional, Charney, Alexander, additional, Firpo-Betancourt, Adolfo, additional, Mendu, Damodara Rao, additional, Jhang, Jeffrey, additional, Reich, David, additional, Sigel, Keith, additional, Cordon-Cardo, Carlos, additional, Feldmann, Marc, additional, Parekh, Samir, additional, Merad, Miriam, additional, and Gnjatic, Sacha, additional

Published
2020
Full Text
View/download PDF

218. Mutation-derived Neoantigen-specific T-cell Responses in Multiple Myeloma

Author

Perumal, Deepak, primary, Imai, Naoko, additional, Laganà, Alessandro, additional, Finnigan, John, additional, Melnekoff, David, additional, Leshchenko, Violetta V., additional, Solovyov, Alexander, additional, Madduri, Deepu, additional, Chari, Ajai, additional, Cho, Hearn Jay, additional, Dudley, Joel T., additional, Brody, Joshua D., additional, Jagannath, Sundar, additional, Greenbaum, Benjamin, additional, Gnjatic, Sacha, additional, Bhardwaj, Nina, additional, and Parekh, Samir, additional

Published
2020
Full Text
View/download PDF

222. Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studies.

Author

Cohen, Adam D., Parekh, Samir, Santomasso, Bianca D., Pérez-Larraya, Jaime Gállego, van de Donk, Niels W. C. J., Arnulf, Bertrand, Mateos, Maria-Victoria, Lendvai, Nikoletta, Jackson, Carolyn C., De Braganca, Kevin C., Schecter, Jordan M., Marquez, Loreta, Lee, Erin, Cornax, Ingrid, Zudaire, Enrique, Li, Claire, Olyslager, Yunsi, Madduri, Deepu, Varsos, Helen, and Pacaud, Lida

Subjects
MULTIPLE myeloma, CYTOKINE release syndrome, NEUROTOXICOLOGY, CHIMERIC antigen receptors
Abstract

Chimeric antigen receptor (CAR) T-cell therapies are highly effective for multiple myeloma (MM) but their impressive efficacy is associated with treatment-related neurotoxicities in some patients. In CARTITUDE-1, 5% of patients with MM reported movement and neurocognitive treatment-emergent adverse events (MNTs) with ciltacabtagene autoleucel (cilta-cel), a B-cell maturation antigen-targeted CAR T-cell therapy. We assessed the associated factors for MNTs in CARTITUDE-1. Based on common features, patients who experienced MNTs were characterized by the presence of a combination of at least two variables: high tumor burden, grade ≥2 cytokine release syndrome (CRS) or any grade immune effector cell-associated neurotoxicity syndrome (ICANS) after cilta-cel infusion, and high CAR T-cell expansion/persistence. Strategies were implemented across the cilta-cel development program to monitor and manage patients with MNTs, including enhanced bridging therapy to reduce baseline tumor burden, early aggressive treatment of CRS and ICANS, handwriting assessments for early symptom detection, and extended monitoring/reporting time for neurotoxicity beyond 100 days post-infusion. After successful implementation of these strategies, the incidence of MNTs was reduced from 5% to <1% across the cilta-cel program, supporting its favorable benefit–risk profile for treatment of MM. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

223. Transmission of Eastern Equine Encephalitis Virus from an Organ Donor to Three Transplant Recipients

Author

Pouch, Stephanie M., Katugaha, Shalika B., Shieh, Wun-Ju, Annambhotla, Pallavi, Walker, William L., Basavaraju, Sridhar V., Jones, Jefferson, Huynh, Thanhthao, Reagan-Steiner, Sarah, Bhatnagar, Julu, Grimm, Kacie, Stramer, Susan L., Gabel, Julie, Lyon, G. Marshall, Mehta, Aneesh K., Kandiah, Prem, Neujahr, David C., Javidfar, Jeffrey, Subramanian, Ram M., Parekh, Samir M., Shah, Palak, Cooper, Lauren, Psotka, Mitchell A., Radcliffe, Rachel, Williams, Carl, Zaki, Sherif R., Staples, J. Erin, Fischer, Marc, Panella, Amanda J., Lanciotti, Robert S., Laven, Janeen J., Kosoy, Olga, Rabe, Ingrid B., and Gould, Carolyn V.

Subjects
Adult, Encephalomyelitis, Equine, Transplantation, Middle Aged, Article, Medical Records, Tissue Donors, Transplant Recipients, Liver Transplantation, Culicidae, Fatal Outcome, Animals, Encephalitis Virus, Eastern Equine, Heart Transplantation, Humans, Female, Lung Transplantation
Abstract

BACKGROUND: In fall 2017, three solid organ transplant recipients from a common donor developed encephalitis within one week of transplantation, prompting suspicion of transplant-transmitted infection. Eastern equine encephalitis virus (EEEV) infection was identified during testing of endomyocardial tissue from the heart recipient. METHODS: We reviewed medical records of the organ donor and transplant recipients and tested serum, whole blood, cerebrospinal fluid, and tissue from the donor and recipients for evidence of EEEV infection by multiple assays. We investigated blood transfusion as a possible source of organ donor infection by testing remaining components and serum specimens from blood donors. We reviewed data from the pre-transplant organ donor evaluation and local EEEV surveillance. RESULTS: We found laboratory evidence of recent EEEV infection in all organ recipients and the common donor. Serum collected from the organ donor upon hospital admission tested negative, but subsequent samples obtained prior to organ recovery were positive for EEEV RNA. There was no evidence of EEEV infection among donors of the eight blood products transfused into the organ donor or in products derived from these donations. Veterinary and mosquito surveillance showed recent EEEV activity in counties nearby the organ donor’s county of residence. Neuroinvasive EEEV infection directly contributed to the death of one organ recipient and likely contributed to death in another. CONCLUSIONS: Our investigation demonstrated EEEV transmission through solid organ transplantation. Mosquito-borne transmission of EEEV to the organ donor was the likely source of infection. Clinicians should be aware of EEEV as a cause of transplant-associated encephalitis.

Published
2019

227. Cellular Immune Composition in Multiple Myeloma Patients Associated with Variable Humoral Responses to Sars-Cov-2 Vaccination

Author

Kogan Zajdman, Ariel, Aleman, Adolfo, Upadhyaya, Bhaskar, Beach, Katherine F., Serebryakova, Kseniya, Agte, Sarita, Kappes, Katerina, Gleason, Charles R., Srivastava, Komal, Van Oekelen, Oliver, Cordon-Cardo, Carlos, Krammer, Florian, Merad, Miriam, Jagannath, Sundar, Wajnberg, Ania, Simon, Viviana, and Parekh, Samir

Published
2022
Full Text
View/download PDF

228. Extramedullary Relapse Post CAR-T

Author

Richard, Shambavi, Lancman, Guido, Rossi, Adriana, Chari, Ajai, Parekh, Samir, Sanchez, Larysa, Rodriguez, Cesar, Cho, Hearn J., Richter, Joshua, Thibaud, Santiago, Purcell, Kiah, Aronson, Elizabeth, Verina, Daniel, Escalon, Juliet, Louw, Karen, and Jagannath, Sundar

Published
2022
Full Text
View/download PDF

231. Oral Selinexor–Dexamethasone for Triple-Class Refractory Multiple Myeloma

Author

Chari, Ajai, Vogl, Dan, Gavriatopoulou, Maria, Nooka, Ajay, Yee, Andrew J., Huff, Carol A., Moreau, Philippe, Dingli, David, Cole, Craig, Lonial, Sagar, Dimopoulos, Meletios, Stewart, A Keith, Richter, Joshua, Vij, Ravi, Tuchman, Sascha, Raab, Marc, Weisel, Katja C., Delforge, Michel, Cornell, Robert, Kaminetzky, David, Hoffman, James E., Costa, Luciano J., Parker, Terri, Levy, Moshe, Schreder, Martin, Meuleman, Nathalie, Frenzel, Laurent, Mohty, Mohamad, Choquet, Sylvain, Schiller, Gary, Comenzo, Raymond, Engelhardt, Monika, Illmer, Thomas, Vlummens, Philip, Doyen, Chantal, Facon, Thierry, Karlin, Lionel, Perrot, Aurore, Podar, Klaus, Kauffman, Michael, Shacham, Sharon, Li, Lingling, Tang, Shijie, Picklesimer, Carla, Saint-Martin, Jean-Richard, Crochiere, Marsha, Chang, Hua, Parekh, Samir, Landesman, Yosef, Shah, Jatin, Richardson, Paul G., Jagannath, Sundar, Chari, Ajai, Vogl, Dan, Gavriatopoulou, Maria, Nooka, Ajay, Yee, Andrew J., Huff, Carol A., Moreau, Philippe, Dingli, David, Cole, Craig, Lonial, Sagar, Dimopoulos, Meletios, Stewart, A Keith, Richter, Joshua, Vij, Ravi, Tuchman, Sascha, Raab, Marc, Weisel, Katja C., Delforge, Michel, Cornell, Robert, Kaminetzky, David, Hoffman, James E., Costa, Luciano J., Parker, Terri, Levy, Moshe, Schreder, Martin, Meuleman, Nathalie, Frenzel, Laurent, Mohty, Mohamad, Choquet, Sylvain, Schiller, Gary, Comenzo, Raymond, Engelhardt, Monika, Illmer, Thomas, Vlummens, Philip, Doyen, Chantal, Facon, Thierry, Karlin, Lionel, Perrot, Aurore, Podar, Klaus, Kauffman, Michael, Shacham, Sharon, Li, Lingling, Tang, Shijie, Picklesimer, Carla, Saint-Martin, Jean-Richard, Crochiere, Marsha, Chang, Hua, Parekh, Samir, Landesman, Yosef, Shah, Jatin, Richardson, Paul G., and Jagannath, Sundar

Abstract

info:eu-repo/semantics/published

Published
2019

232. Selinexor, bortezomib, and dexamethasone (SVD) in heavily treated relapsed refractory multiple myeloma.

Author

Mouhieddine, Tarek H., Parekh, Samir, Cho, Hearn Jay, Richter, Joshua, DeCastro, Andrew, Shah, Jatin, Landesman, Yosef, Chari, Ajai, Jagannath, Sundar, and Madduri, Deepu

Subjects
*MULTIPLE myeloma, *STEM cell transplantation, *BORTEZOMIB, *PLASMA cell leukemia, *DEXAMETHASONE, *NUCLEOCYTOPLASMIC interactions
Abstract

Four patients had extramedullary disease, including plasma cell leukemia with leptomeningeal involvement, and 2/4 patients had a PR. Dear Editor, Multiple myeloma (MM) is a plasma cell dyscrasia that eventually becomes refractory to all available therapies. [Extracted from the article]

Published
2021
Full Text
View/download PDF

235. A Prospective Multicenter Phase 2 Study of Dose-Adjusted-EPOCH-R in Untreated MYC-Rearranged Aggressive B-cell Lymphoma

Author

Dunleavy, Kieron, Fanale, Michelle A., Abramson, Jeremy S., Noy, Ariela, Caimi, Paolo Fabrizio, Pittaluga, Stefania, Parekh, Samir, Lacasce, Ann, Hayslip, John W, Jagadeesh, Deepa, Nagpal, Sunil, Lechowicz, Mary Jo, Gaur, Rakesh, Lucas, Andrea, Melani, Christopher, Roschewski, Mark, Steinberg, Seth M., Jaffe, Elaine S., Kahl, Brad, Friedberg, Jonathan W., Little, Richard F., Bartlett, Nancy L., and Wilson, Wyndham H.

Subjects
hemic and lymphatic diseases, Article
Abstract

BACKGROUND: MYC gene rearrangement (MYC-R) is present in approximately 10% of aggressive B-cell lymphomas with approximately half harboring a BCL2 gene rearrangement (BCL2-R). Multiple retrospective studies of R-CHOP show an inferior outcome in patients with MYC-R, both alone and with BCL2-R and/or BCL6-R, and suggest better outcomes with more aggressive treatment. In the current study, we aimed to determine the outcome of DA-EPOCH-R, an aggressive infusional treatment regimen, in untreated MYC-R aggressive B-cell lymphomas. METHODS: Final analysis of a prospective multi-center study of DA-EPOCH-R (dose-adjusted treatment: etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin and rituxiomab) in 53 patients with untreated MYC-R aggressive B-cell lymphomas. DAEPOCH-R was scheduled to be administered with central nervous system prophylaxis for 6 cycles. Primary endpoints included event-free and overall survival. The study was registered at ClinicalTrials.gov (NCT01092182). FINDINGS: Patient characteristics included median age 61 (range 29–80) years, stage III/IV disease in 43 (81%), and high-intermediate/high international prognostic score (IPI) in 26 (49%) patients. Characteristics were similar among patients with confirmed MYC-R single-hit (n=19) versus those with a BCL2-R and/or BCL6-R, termed double-hit, (n=24) lymphomas. With a median follow up of 55.6 (Interquartile range: 50.5–61.1) months, the 48-month EFS and OS for all patients was 71% and 77%, respectively, with no differences among patients with single versus double-hit tumors or age < versus ≥ 60 years. The EFS at 48-months for low/low-intermediate (0–2) versus high-intermediate/high (3–5) IPI was 89% versus 50%, respectively, for all patients, and 92% versus 55% for double-hit patients. Toxicity included grade 4 neutropenia and thrombocytopenia on 53% and 13% of cycles, respectively, and fever with neutropenia occurred on 19% of cycles. There were 3 treatment related deaths. INTERPRETATION: In this study, DA-EPOCH-R produced durable remissions in MYC-R aggressive B-cell lymphomas and should be considered for the treatment of these diseases. FUNDING: Cancer Trials Support Unit and Center for Cancer Research, National Cancer Institute, USA, and Genentech Inc.

Published
2018

236. Recapturing disease response: A phase 2 study of carfilzomib 56 mg/m 2 in patients with relapsed or refractory multiple myeloma who have progressed on carfilzomib 27 mg/m 2

Author

Barley, Kevin, primary, Sanchez, Larysa, additional, Cho, Hearn J., additional, Parekh, Samir, additional, Madduri, Deepu, additional, Richter, Joshua, additional, Isola, Luis, additional, Goldstein, Talia, additional, Dhadwal, Amishi, additional, Zarychta, Katarzyna, additional, Sanchez, Gillian Morgan, additional, Catamero, Donna, additional, Verina, Daniel, additional, Florendo, Erika, additional, Yum, Moon‐hee, additional, La, Lisa, additional, Gullie, Jude, additional, Chan, Elaine, additional, Jagannath, Sundar, additional, and Chari, Ajai, additional

Published
2019
Full Text
View/download PDF

237. Discovery of a first-in-class EZH2 selective degrader

Author

Ma, Anqi, primary, Stratikopoulos, Elias, additional, Park, Kwang-Su, additional, Wei, Jieli, additional, Martin, Tiphaine C., additional, Yang, Xiaobao, additional, Schwarz, Megan, additional, Leshchenko, Violetta, additional, Rialdi, Alexander, additional, Dale, Brandon, additional, Lagana, Alessandro, additional, Guccione, Ernesto, additional, Parekh, Samir, additional, Parsons, Ramon, additional, and Jin, Jian, additional

Published
2019
Full Text
View/download PDF

238. Outcomes in Multiple Myeloma Patients Progressing on Lenalidomide Maintenance

Author

Sanchez, Larysa, primary, Moshier, Erin, additional, Coltoff, Alexander, additional, Mustafa, Ali, additional, Pan, Darren, additional, Cho, Hearn Jay, additional, Jagannath, Sundar, additional, Madduri, Deepu, additional, Parekh, Samir, additional, Richard, Shambavi, additional, Richter, Joshua, additional, and Chari, Ajai, additional

Published
2019
Full Text
View/download PDF

240. Targeting Hypersumoylation in Mantle Cell Lymphoma

Author

Hanel, Walter, primary, Tsyba, Liudmyla, additional, Huszar, Dennis, additional, Prouty, Alex, additional, Zhang, Xiaoli, additional, Helmig-Mason, JoBeth, additional, Mundy-Bosse, Bethany L, additional, Youssef, Youssef, additional, Parekh, Samir, additional, Maddocks, Kami J., additional, Baiocchi, Robert A, additional, and Alinari, Lapo, additional

Published
2019
Full Text
View/download PDF

241. ADAR1 Drives Disease Progression in Multiple Myeloma By Acting Both As an RNA Editor of Specific Transcripts and As a DNA Mutator of Their Cognate Genes

Author

Tasakis, Rafail Nikolaos, primary, Lagana, Alessandro, additional, Leshchenko, Violetta, additional, Melnekoff, David, additional, Beno, Itai, additional, Keats, Jonathan J, additional, Auclair, Daniel, additional, Madduri, Deepu, additional, Richter, Joshua, additional, Chari, Ajai, additional, Cho, Hearn Jay, additional, Jagannath, Sundar, additional, Dudley, Joel, additional, Papavasiliou, F. Nina, additional, and Parekh, Samir, additional

Published
2019
Full Text
View/download PDF

242. High Dimensional Immune Profiling in Smoldering Multiple Myeloma Identifies Novel Organizing Features of the Tumor Microenvironment

Author

Cho, Hearn Jay, primary, Perumal, Deepak, additional, Rahman, Adeeb H, additional, Kim-Schultze, Seunghee, additional, Yesil, Jennifer, additional, Auclair, Daniel, additional, Casneuf, Tineke, additional, Adams, Homer, additional, Parekh, Samir, additional, Gnjatic, Sacha, additional, and Fernandez, Nicolas, additional

Published
2019
Full Text
View/download PDF

243. Multidimensional Single Cell Analysis Shows Increased T/NK Cell Subsets in Both Blood and Bone Marrow of Iberdomide (CC-220) Treated Relapsed/Refractory Multiple Myeloma Patients

Author

Amatangelo, Michael, primary, Van Oekelen, Oliver, additional, Rahman, Adeeb H, additional, Lagana, Alessandro, additional, Gooding, Sarah, additional, Avet-Loiseau, Hervé, additional, Oppermann, Udo, additional, Pierceall, William E, additional, Thakurta, Anjan, additional, and Parekh, Samir, additional

Published
2019
Full Text
View/download PDF

244. A Machine Learning Approach Identifies a 30-Gene Model That Predicts Sensitivity to Selinexor in Multiple Myeloma

Author

Lagana, Alessandro, primary, Bhalla, Sherry, additional, Aleman, Adolfo, additional, Mei, Anna Huo-Chang, additional, Leshchenko, Violetta, additional, Landesman, Yosef, additional, Melnekoff, David, additional, Beno, Itai, additional, Madduri, Deepu, additional, Richter, Joshua R, additional, Chari, Ajai, additional, Cho, Hearn Jay, additional, Jagannath, Sundar, additional, Dudley, Joel, additional, and Parekh, Samir, additional

Published
2019
Full Text
View/download PDF

245. Minimal Residual Disease (MRD) Assessment in the ECOG1411 Randomized Phase 2 Trial of Front-Line Bendamustine-Rituximab (BR)-Based Induction Followed By Rituximab (R) ± Lenalidomide (L) Consolidation for Mantle Cell Lymphoma (MCL)

Author

Smith, Mitchell, primary, Jegede, Opeyemi, primary, Parekh, Samir, primary, Hanson, Curtis A., primary, Martin, Peter, primary, Till, Brian G., primary, Crump, Michael, primary, Leonard, John P., primary, Friedberg, Jonathan W., primary, Kahl, Brad S., primary, and Witzig, Thomas E., primary

Published
2019
Full Text
View/download PDF

249. Oral Selinexor–Dexamethasone for Triple-Class Refractory Multiple Myeloma

Author

Chari, Ajai, primary, Vogl, Dan T., additional, Gavriatopoulou, Maria, additional, Nooka, Ajay K., additional, Yee, Andrew J., additional, Huff, Carol A., additional, Moreau, Philippe, additional, Dingli, David, additional, Cole, Craig, additional, Lonial, Sagar, additional, Dimopoulos, Meletios, additional, Stewart, A. Keith, additional, Richter, Joshua, additional, Vij, Ravi, additional, Tuchman, Sascha, additional, Raab, Marc S., additional, Weisel, Katja C., additional, Delforge, Michel, additional, Cornell, Robert F., additional, Kaminetzky, David, additional, Hoffman, James E., additional, Costa, Luciano J., additional, Parker, Terri L., additional, Levy, Moshe, additional, Schreder, Martin, additional, Meuleman, Nathalie, additional, Frenzel, Laurent, additional, Mohty, Mohamad, additional, Choquet, Sylvain, additional, Schiller, Gary, additional, Comenzo, Raymond L., additional, Engelhardt, Monika, additional, Illmer, Thomas, additional, Vlummens, Philip, additional, Doyen, Chantal, additional, Facon, Thierry, additional, Karlin, Lionel, additional, Perrot, Aurore, additional, Podar, Klaus, additional, Kauffman, Michael G., additional, Shacham, Sharon, additional, Li, Lingling, additional, Tang, Shijie, additional, Picklesimer, Carla, additional, Saint-Martin, Jean-Richard, additional, Crochiere, Marsha, additional, Chang, Hua, additional, Parekh, Samir, additional, Landesman, Yosef, additional, Shah, Jatin, additional, Richardson, Paul G., additional, and Jagannath, Sundar, additional

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results